Mounjaro®
Starting from £179.99/mo
Start journey Learn moreAfter a single subcutaneous injection, tirzepatide reaches its peak concentration in the bloodstream within around 24 to 72 hours. That absorption window is well-characterised in the prescribing data, but peak plasma level and noticeable weight-loss effects are two very different things. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is clinically appropriate for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide is injected subcutaneously, into the fatty tissue just beneath the skin of the abdomen, thigh or upper arm. From there it is absorbed slowly into the bloodstream rather than reaching it all at once. According to the Mounjaro prescribing information published on the electronic Medicines Compendium, peak plasma concentration is reached somewhere between one and three days after a single dose, and if you want to understand how long Mounjaro takes to get into your system in more detail, we cover that fully in a dedicated guide. That is slower than an oral tablet but is precisely what makes a once-weekly schedule practical.
During those first hours, the medicine is present in your system but at levels that are still climbing. You will not feel a dramatic shift. Some people notice a mild reduction in appetite or very slight nausea as the dose rises, these are early signs the medicine is active, not a problem. Others feel nothing at all in week one, which is equally normal. The 2.5 mg starting pen exists specifically to let your digestive system acclimatise; the prescriber, not you, decides when and whether to move up.
The NHS medicines page for tirzepatide describes the common early side effects in plain language and is worth reading before your first injection.
Tirzepatide has a half-life of roughly five days. That means it takes around four to five weeks of weekly dosing before the medicine reaches a true steady state in your blood, the point at which levels between injections stabilise rather than continuing to rise. This accumulation phase matters for understanding your experience, and our guide on how quickly Mounjaro gets into your system explains what is happening during this period in plain terms.
Many people find that hunger reduces noticeably somewhere in weeks two to three. Food feels less urgent. Portions that felt modest before feel adequate. This is the dual GIP and GLP-1 receptor activity doing its job: slowing gastric emptying and signalling fullness to the brain. For some, the shift is subtle enough that they only notice it in retrospect. For others it is the most striking change they have ever experienced with a weight-management approach.
If you are curious about the broader arc of how Mounjaro works over a full course of treatment, the guide to how long Mounjaro takes to work covers what the trial data shows at each phase of titration.
The distinction between the medicine being active in your system and visible results is often the source of the most questions our prescribers hear. Tirzepatide reaches steady state within a month, but the body then has to respond over weeks: reduced appetite leads to a calorie deficit, which over time produces measurable weight loss. For most people on 2.5 mg or 5 mg, meaningful scale change becomes apparent between four and eight weeks. Results build steadily as the dose is titrated upward under clinical supervision.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed thousands of adults over 72 weeks and found average body-weight reductions of around 20–21% at the 15 mg dose, figures that accumulated gradually across the full treatment period, not in the first few weeks. That context is useful: Mounjaro is not a rapid purge. It is a sustained, progressive process.
The cost of treatment is a fair question at this stage. How Mounjaro is priced privately in the UK, and what a legitimate prescription service includes, is covered on the weight-loss treatment overview.
How long tirzepatide remains detectable and active after you stop is a separate question, and you can read about how long Mounjaro lasts in your system on its own dedicated page, alongside the related question of how long Mounjaro is in your system altogether after a course of treatment. If you are also wondering about clearance times more broadly, our dedicated page on how long Mounjaro stays in your system walks through what the pharmacokinetic data tells us about elimination.
A few practical factors can affect how quickly you notice Mounjaro working. Injection technique matters: if the pen is not pressed firmly enough or the site is not rotated, absorption can be inconsistent. Storage is another variable, pens kept outside the 2–8°C fridge range for longer than the SmPC allows may lose potency; check the Patient Information Leaflet for the exact permitted room-temperature window rather than estimating. Lifestyle also plays a role. The trial data was generated alongside a reduced-calorie diet and increased activity; those two factors amplify what the medicine can do.
It is also worth remembering that titration is gradual by design. Jumping from 2.5 mg to a higher strength too quickly in the hope of faster results is not how the licensed schedule works, and dose decisions rest with your prescriber, not the calendar. If four to six weeks at your current dose has produced very little change, that is a conversation to have with your clinical team rather than a reason to self-adjust.
The frequently asked questions page covers common concerns about the treatment schedule. If you have a specific query for our team, the contact page lists the fastest ways to reach us.
If you are thinking about starting treatment and want to understand whether Mounjaro could be right for you, a free consultation with a GPhC-registered prescriber at nume is the straightforward next step. There are no subscriptions and no hidden charges, a prescriber reviews your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.